Bremelanotide, commonly known as PT-141 in research contexts, is a synthetic cyclic heptapeptide that has garnered significant interest among peptide researchers due to its selective activity at melanocortin receptor subtypes. This compound originates from alpha-melanocyte-stimulating hormone (α-MSH) and has been extensively investigated in preclinical settings for its capacity to activate central melanocortin pathways—a receptor system implicated in far more than pigmentation biology. Scientists focused on neuropeptide pharmacology, hypothalamic regulation, and autonomic nervous system function view PT-141 as a critical research tool for understanding melanocortin receptor-mediated behavioral and physiological responses.
With growing research emphasis on melanocortin receptor biology across neuroscience disciplines, PT-141 has become one of the more thoroughly characterized peptides in this category. The cyclic backbone provides enhanced metabolic stability relative to linear peptide sequences, establishing PT-141 as a reference molecule for laboratory investigations into receptor selectivity, intracellular signaling, and peptide structure-activity relationships in controlled experimental environments.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. PT-141 is a reference compound intended solely for in-vitro and preclinical laboratory research. It is not intended for human or animal use.
Frequently Asked Questions
What is PT-141 and how is it classified in peptide research?
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). In research contexts, it is classified as a melanocortin receptor agonist, studied primarily for its activity at MC1R, MC3R, and MC4R receptor subtypes in preclinical models.
Which melanocortin receptors does PT-141 interact with in preclinical studies?
Preclinical research has investigated PT-141's binding affinity across multiple melanocortin receptor subtypes, with particular focus on MC3R and MC4R, which are distributed throughout the central nervous system and have been linked to autonomic and behavioral signaling pathways in animal models.
How does PT-141 differ structurally from alpha-MSH?
PT-141 is a cyclic analog derived from α-MSH, modified to improve metabolic stability and receptor binding. The cyclization of the peptide backbone reduces enzymatic degradation compared to the linear α-MSH sequence, making it a more tractable molecule for preclinical receptor binding and signaling studies.
What biological pathways has PT-141 been studied in connection with?
Research has investigated PT-141 in relation to hypothalamic melanocortin signaling, autonomic nervous system pathways, and central nervous system receptor biology. Preclinical models have examined its interactions with reward circuitry, neuroendocrine axes, and downstream cAMP-mediated signaling cascades.
Is PT-141 the same compound as Melanotan-2?
PT-141 and Melanotan-2 (MT-2) are structurally related but distinct compounds. MT-2 is a cyclic analog of α-MSH studied for its melanotropic properties, while PT-141 was developed from MT-2 as a metabolite and is studied for its more selective central melanocortin receptor activity in preclinical models.
What does MC4R activation represent in basic neuroscience research?
MC4R (melanocortin-4 receptor) is expressed in hypothalamic and limbic brain regions and has been studied in preclinical neuroscience as a regulator of autonomic tone, energy homeostasis signaling, and reward-related behavioral circuits. PT-141's activity at this receptor makes it a useful tool compound for probing these pathways in laboratory settings.
Where can researchers source PT-141 for laboratory use?
Research-grade PT-141 is available from specialized peptide suppliers for in-vitro and preclinical laboratory applications. It is supplied as a lyophilized reference compound intended exclusively for scientific research purposes.
Understanding the Melanocortin Receptor System
Appreciating PT-141's position in modern peptide research requires foundational knowledge of the melanocortin system itself. This receptor family consists of five G-protein-coupled receptor (GPCR) subtypes—MC1R through MC5R—each with unique tissue expression patterns and signaling characteristics. These receptors recognize endogenous ligands including α-MSH, β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH), all of which originate from the proopiomelanocortin (POMC) precursor protein.
Within central nervous system research, MC3R and MC4R have received considerable attention. MC4R demonstrates high expression density in hypothalamic nuclei, and animal studies have connected its activation to autonomic outflow modulation, neuroendocrine control, and behavioral signaling cascades. MC3R, found in hypothalamic and limbic regions, has been investigated in preclinical research for its involvement in energy homeostasis and reward pathway signaling. These receptor subtypes constitute valuable research targets for scientists examining neuropeptide function and CNS biology.
POMC-Derived Peptides and Receptor Selectivity
One fundamental challenge facing melanocortin researchers involves achieving receptor subtype selectivity, as native peptides like α-MSH demonstrate promiscuous binding across multiple receptor subtypes. Synthetic analogs such as PT-141 have been developed to provide researchers with more selective tools for interrogating individual receptor subtypes. Binding kinetics studies using recombinant melanocortin receptors have helped characterize PT-141's selectivity profile and map the structural features within the His-Phe-Arg-Trp (HFRW) core pharmacophore—the essential tetrapeptide sequence required for melanocortin receptor recognition.
Structural Features and Stability Characteristics of PT-141
The molecular architecture of PT-141 consists of a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. A lactam bridge between aspartic acid and lysine residues constrains the peptide into its bioactive conformation. Peptide chemistry researchers focus on this structural element because it dramatically reduces proteolytic susceptibility, making the molecule substantially more stable as a laboratory reference compound than its linear counterparts.
Another structurally important modification is the D-Phe substitution at position 7—replacing the L-Phe found in native α-MSH. Researchers have noted this change for its contribution to enhanced receptor binding affinity and prolonged receptor engagement in preclinical binding experiments. This modification is also present in related compounds like Melanotan-2, and investigating structure-activity relationships at this position remains an active area of peptide chemistry research.
Preclinical Investigations: Central Nervous System Signaling
Hypothalamic Circuit Research
Extensive preclinical work has investigated PT-141's engagement with hypothalamic melanocortin circuits. Animal model experiments have shown that melanocortin receptor activation in hypothalamic regions—particularly the paraventricular nucleus (PVN) and medial preoptic area (MPOA)—influences autonomic nervous system output. Rodent studies have provided evidence that MC4R activation in these areas initiates cAMP-dependent signaling cascades that regulate physiological responses linked to autonomic control.
Investigators have also examined intersections between melanocortin signaling and dopaminergic reward systems. Preclinical animal data suggest that MC4R agonism can influence mesolimbic dopamine activity, providing researchers with a molecular framework for studying how hypothalamic peptide signaling interfaces with reward-related neural networks. This research connects to broader neuroscience efforts examining neuropeptide regulation of motivational states at the neurobiological level. Researchers exploring cognitive and brain-related peptide systems may find parallel frameworks in studies examining nootropic peptide mechanisms in preclinical brain models.
Autonomic and Cardiovascular Research Observations
Multiple preclinical investigations have examined cardiovascular correlates of central melanocortin receptor activation. Animal research has documented transient blood pressure parameter changes following central administration of melanocortin agonists, attributed to MC4R-mediated sympathetic nervous system modulation. These observations have interested researchers mapping neuroendocrine-cardiovascular interactions, though findings remain restricted to preclinical contexts and require additional mechanistic characterization.
Comparing PT-141 and Melanotan-2: Related but Distinct Research Tools
| Feature | PT-141 (Bremelanotide) | Melanotan-2 (MT-2) |
|---|---|---|
| Structural class | Cyclic heptapeptide (lactam-bridged) | Cyclic heptapeptide (disulfide analog) |
| Primary receptor focus | MC3R / MC4R (central CNS focus) | MC1R / MC3R / MC4R (broader profile) |
| Research area emphasis | Hypothalamic, autonomic, CNS signaling | Melanogenesis, pigmentation biology, CNS |
| Metabolic stability | Enhanced via lactam cyclization + D-Phe | Enhanced via cyclization |
| Origin | Derived as a metabolite/analog of MT-2 | Derived from α-MSH |
| Key preclinical model use | Autonomic modulation, reward circuitry | Pigmentation, metabolic signaling |
Though PT-141 and MT-2 share common structural ancestry and both engage melanocortin receptors, their research applications differ substantially. MT-2 has been studied more extensively in melanogenesis and pigmentation models, while PT-141 research emphasizes central melanocortin receptor function. Researchers choosing between these compounds for laboratory work should consider the specific receptor subtypes and biological pathways relevant to their experimental objectives.
Choose PT-141 if...
- The research focus is on MC3R or MC4R receptor biology in central nervous system preparations
- Studies involve hypothalamic signaling, autonomic nervous system circuitry, or reward pathway biology
- Greater metabolic stability in aqueous assay conditions is a priority for the experimental design
- The investigation centers on structure-activity relationships within the HFRW pharmacophore in a CNS receptor context
Choose MT-2 if...
- The research focus is on melanogenesis, pigmentation biology, or MC1R-mediated signaling in melanocyte preparations
- Studies require a broader melanocortin receptor binding profile across MC1R through MC4R subtypes
- Investigations involve metabolic signaling correlates of melanotropic peptide activity
Melanocortin Receptor Agonism in Neuropeptide Research
PT-141's research value extends beyond its receptor binding characteristics. As a tool compound, it has aided investigators in mapping melanocortin receptor subtype functional architecture, contributing to expanding knowledge about how central neuropeptide systems orchestrate complex physiological responses. Researchers working in related domains—such as those investigating neuropeptide analogs in preclinical cognitive models—will recognize the shared conceptual approach: synthetic peptide analogs, through their structural precision, enable researchers to dissect receptor-mediated signaling with greater specificity than endogenous ligands permit.
PT-141 has also contributed to research examining melanocortin-opioid receptor interaction hypotheses, given animal model evidence suggesting cross-talk between melanocortin and endogenous opioid signaling. This area of neuropeptide interaction biology remains an active research frontier, with PT-141 serving as a valuable reference molecule for investigating these receptor systems.
In-Vitro Applications and Receptor Binding Assays
In laboratory environments, PT-141 is commonly utilized in competitive binding assays employing recombinant melanocortin receptor preparations, enabling researchers to characterize binding kinetics, IC₅₀ values, and receptor occupancy profiles. Cell-based functional assays measuring cAMP accumulation following MC4R activation represent another frequent application, helping researchers quantify agonist potency and compare PT-141's efficacy against other synthetic melanocortin analogs. These assay systems demand high-purity peptide reference materials, emphasizing the importance of sourcing research-grade compounds from reputable suppliers. For comprehensive sourcing options, researchers can explore research-grade peptide reference compounds from established suppliers.
Related Research Compounds for Melanocortin and Neuropeptide Studies
Researchers developing comprehensive neuropeptide or melanocortin-focused compound libraries may benefit from exploring related peptides that intersect with PT-141's biological scope. For scientists studying GH secretagogue biology alongside neuropeptide signaling, complementary research domains highlight how different GPCR-targeting peptides modulate distinct yet overlapping neuroendocrine axes.
Where These Fit in Your Research Library
PT-141 occupies a specific niche within the melanocortin peptide research toolkit. For investigators assembling comprehensive neuropeptide reference libraries, it pairs effectively with MT-2 for comparative receptor binding investigations, and with neuropeptides such as oxytocin and kisspeptin for multi-system autonomic and neuroendocrine signaling research.
Concluding Perspective: PT-141 as a Melanocortin Research Tool
PT-141 represents one of the most structurally refined and comprehensively studied synthetic melanocortin receptor agonists available for preclinical research. Its cyclic architecture, D-Phe substitution, and selective MC3R and MC4R engagement establish it as a valuable tool for dissecting central melanocortin signaling in hypothalamic, limbic, and autonomic research contexts. Preclinical investigations have established mechanistic data linking PT-141 to cAMP-mediated receptor signaling, hypothalamic neuroendocrine function, and reward circuit modulation in animal models—areas that continue to generate substantial scientific interest. For laboratory investigators requiring a well-characterized melanocortin reference compound, PT-141 remains among the most compelling options in the current research peptide landscape.
Sources & Further Reading
- Molinoff PB et al. — "PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction" — Annals of the New York Academy of Sciences (2003)
- Wikberg JE — "Melanocortin Receptors: Perspectives for Novel Drugs" — European Journal of Pharmacology (1999)
- Giuliano F et al. — "Neurophysiology and Pharmacology of Female Genital Sexual Response" — Journal of Sex & Marital Therapy (2004)
- Hadley ME & Dorr RT — "Melanocortin Peptide Therapeutics: Historical Milestones, Clinical Studies, and Future Directions" — Peptides (2006)
- PubMed Search — PT-141 Melanocortin Receptor Research Literature
Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Originally published at https://www.sourcepeptides.co/2026/07/24/pt-141-peptide-research-guide-mechanisms-melanocortin-biology-preclinical-study-findings-2026/.
Top comments (0)